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Abstract: Inﬂ  iximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of 
moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) 
remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe 
the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the 
efﬁ  cacy of inﬂ  iximab in the treatment of moderate to severe UC.
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Introduction
Ulcerative colitis (UC) is a chronic remitting and relapsing disease characterized by 
mucosal inﬂ  ammation of the colon. The extent of disease varies from limited involve-
ment of the rectum to involvement of the whole colon. Rarely, there is mild involvement 
of the distal part of the ileum, which is believed to be an “overﬂ  ow” of inﬂ  ammation 
from the cecum and is called backwash ileitis (Podolsky 2002).
UC manifests clinically as bloody diarrhea, abdominal pain, urgency, and tenesmus. 
In more severe cases, patients may develop systemic features, such as fever, tachy-
cardia, nausea, vomiting, anorexia, weight loss, and an elevated CRP and erythrocyte 
sedimentation rate (Baumgart and Sandborn 2007). Clinically mild disease is deﬁ  ned as 
disease associated with fewer than 4 bowel movements a day, with or without blood in 
the stool and without systemic manifestations. In these patients, laboratory results are 
usually within the normal range. Moderate disease describes disease associated with 
more than 4 bowel movements a day with minimal systemic manifestations. Severe 
disease describes disease associated with more than 6 bowel movements a day, with 
blood in the stool and with systemic involvement (D’Haens et al 2007). The clinical 
course of UC is marked by exacerbations and remissions. Treatment of mild to moder-
ate UC consists of oral and/or topical 5-aminosalicylates, oral and/or topical cortico-
steroids, and purine analogs (azathioprine and 6-mercaptopurine) (Carter et al 2004; 
Lichtenstein et al 2006). In 15% of the cases, the disease manifests as an episode of 
severe colitis necessitating hospitalization, administration of intravenous treatment, and 
sometimes colectomy. A small minority of the patients develop a frequently relapsing 
chronic disease (Binder 2004). Approximately 11% of the patients with UC develop 
extraintestinal manifestations over the course of their disease, which can parallel the 
activity of colitis or be independent of colonic disease. These manifestations include: 
small joint arthritis, sacroileitis, ankylosing spondylitis, erythema nodosum, pyoderma 
gangrenosum, apthous ulcers of the oral mucosa, episcleritis, uveitis, and sclerosing 
cholangitis (Danese et al 2005).
Early studies reported a 30% fatality rate for patients referred for a ﬁ  rst attack 
of severe UC. However, as medical and surgical treatments improved, the mortality 
rates declined, and currently patients with UC have an overall normal life expectancy 
(Loftus et al 2000). Some reports even suggest decreased mortality in patients with 
UC compared with the general population (Winther et al 2003). Despite overall good Biologics: Targets & Therapy 2008:2(3) 380
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survival rates, patients have an increased risk of colectomy, 
development of colorectal cancer (Soetikno et al 2002), and 
cholangiocarcinoma (Broome et al 1995).
Despite major advancements in medical therapy, treat-
ment options for patients with moderate to severe UC remain 
limited. Steroid treatment was introduced in the 1950s and 
markedly reduced mortality in severe disease (Truelove and 
Witts 1955). The other remaining medical treatment option 
for patients with severe UC is the addition of cyclosporine. 
Although considered to be highly effective in inducing remis-
sion, double-blind, randomized, controlled trials assessing the 
efﬁ  cacy of cyclosporine in this setting are limited (Lichtiger 
et al 1994; D’Haens et al 2001). Furthermore, cyclosporine 
has a narrow therapeutic index with potentially serious side 
effects, necessitating close monitoring of cyclosporine blood 
levels (Shibolet et al 2005). If treatment with steroids and 
cyclosporine fails to induce remission in severe UC, patients 
are faced with the need for colectomy. Even if patients 
respond to cyclosporine, most will eventually require col-
ectomy (D’Haens et al 2001).
In the face of the paucity of treatment options it was 
essential to identify new therapies for moderate to severe 
UC that are easier to administer, have higher efﬁ  cacy, are 
better tolerated and have a better safety proﬁ  le.
The search for such drugs focused on elucidating the 
pathophysiology of inflammatory bowel disease (IBD) 
(Xavier and Podolsky 2007) and identifying possible drug 
targets (Korzenik and Podolsky 2006). Data from animal 
models of colitis and from human studies suggested that 
treatment with either anti-inﬂ  ammatory cytokines or with 
pro-inﬂ  ammatory cytokine blockers may modulate the course 
of IBD (Elson et al 2005). One of the major pro-inﬂ  ammatory 
cytokines involved in the pathogenesis of IBD was discov-
ered to be tumor necrosis factor-α (TNF-α) (Papadakis and 
Targan 2000). This led to a breakthrough in IBD treatment 
with the introduction of anti-TNF-α antibody treatment that 
was initially used to treat Crohn's disease (Sandborn and 
Hanauer 1999).
Pathogenesis of IBD
Inﬂ  ammatory bowel disease groups together two distinctive 
clinical entities: UC and CD. These two diseases differ in 
their location (colon only for UC vs the whole length of the 
intestinal tract for CD), pattern of distribution (continuous 
vs patchy), depth of involvement (mucosal vs transmural), 
and histology (crypt abscesses vs granulomas). It is there-
fore not surprising that their pathogenesis is considerably 
different. The pathogenesis of IBD has been hypothesized 
to be caused by an inappropriate immune response against 
luminal antigens in a genetically susceptible host resulting in 
uncontrolled intestinal inﬂ  ammation (Xavier and Podolsky 
2007). Inﬂ  ammatory responses are traditionally classiﬁ  ed 
into Th1 or Th2 responses based on the cytokine secretion 
proﬁ  le of differentiated T lymphocytes. Both CD4+ and 
CD8+ T lymphocytes can be identiﬁ  ed as either Th1 cells 
that produce IFNγ, IL-2, IL-12, and IL-18 or Th2 cells that 
secrete IL-4, IL-5, IL-6, IL-10, and IL-13. Recently, another 
type of immune response dubbed Th17 and characterized by 
production of IL-17 by speciﬁ  c IL-17 producing T lympho-
cytes has been described and was shown to play a role in the 
pathogenesis of IBD (Park et al 2005).
CD has been traditionally described as a Th1 mediated 
disease with the predominant cytokines being the pro-inﬂ  am-
matory cytokines IFNγ, IL-1β, and IL-12. These cytokines 
contribute to an increase in mucosal permeability, collagen 
synthesis and recruitment of inﬂ  ammatory cells. Most exist-
ing animal models of experimental colitis are skewed toward 
a Th1 response. These include trinitrobenzene (TNBs) colitis, 
dextran sodium sulfate (DSS) colitis, and the IL-10 knockout 
spontaneous colitis models. Another Th1 mediated granu-
lomatous colitis model has been established by the adoptive 
transfer of normal CD45RBhigh T lymphocytes from Balb/C 
mice into SCID mice (Bouma and Strober 2003).
UC, on the other hand, has been considered to be an 
atypical Th2 mediated disease characterized by CD4+ 
T lymphocytes bearing a natural killer (NK) T lymphocyte 
marker. Levels of IL-4, IL-5, IL-8, but also IL-1β, IL-12, 
and IFNγ, are signiﬁ  cantly higher in patients with UC than 
in healthy controls with a prominence of IL-4 and IL-5. Th2 
predominant animal models of experimental colitis include 
the TCRα and WASP deﬁ  cient mice, oxazolone colitis, and 
spontaneous colitis in cotton-top tamarins (Strober et al 
2002). The recent discovery of Th17 cells and their role in 
IBD (Iwakura and Ishigame 2006) suggests that the Th1/Th2 
hypothesis may represent an oversimpliﬁ  ed model of this 
complex disease.
Despite the immunological and clinical differences 
between UC and CD, both diseases share part of their cyto-
kine proﬁ  le and exhibit elevated levels of TNF-α.
Tumor necrosis factor-α
TNF-α is a cytokine involved in inﬂ  ammatory responses 
and is a member of the TNF-super-family. It is capable of 
killing tumor cells in vitro and causing hemorrhagic necro-
sis of transplantable tumors in mice (Old 1985; Bazzoni 
and Beulter 1996). TNF-α plays a role in multiple human Biologics: Targets & Therapy 2008:2(3) 381
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disease processes including septic shock (Cauwels et al 
2003), cancer/AIDS-associated cachexia (Argiles et al 1997), 
graft-versus-host disease (Jacobsohn and Vogelsang 2004), 
rheumatoid arthritis, and CD (Siddiqui and Scott 2005).
TNF-α is ﬁ  rst produced as a 26-kDa transmembrane 
protein, which can be cleaved by the metalloproteinase-
desintegrin, TNF-α converting enzyme (TACE also known 
as ADAM17) to form a secreted, soluble 17-kDa protein 
(Black et al 1997). Secreted TNF-α (sTNF-α) aggregates 
into trimolecular complexes, which bind and activate the 
TNF receptors, TNF receptor type 1(TNFR1) and TNF 
receptor type 2 (TNFR2). TNFR1 is constitutively expressed 
in most tissues, and can be activated by both the mem-
brane-bound and soluble forms of TNF-α, while TNFR2 is 
expressed in cells of the immune system and responds to the 
membrane-bound form of TNF-α. Following TNF-α bind-
ing, the receptors form trimmers and initiate intracellular 
signaling via 3 main pathways. Inﬂ  ammatory signals are 
conveyed via NF-κB and MAPK pathways, while apoptotic 
signals are conveyed via TRADD, FADD and caspase-8 
(Vassalli 1992).
Monocytes/macrophages are the main source of TNF-α, 
although T and B lymphocytes also produce signiﬁ  cant 
amounts. Other cells known to produce TNF-α include NK 
cells, mast cells, Paneth cells, keratinocytes, astrocytes and 
microglial cells, smooth muscle cells, and certain tumor cell 
lines (Guy-Grand et al 1998; Nilsen et al 1998; Bischoff et al 
1999). TNF-α is also produced by intestinal epithelial cells 
in response to bacterial invasion (Jung et al 1995).
Inﬂ  iximab
Inﬂ  iximab is a chimeric anti-TNF-α mouse monoclonal 
antibody (Baugh and Bucala 2001). Its Fab fragment con-
sists of the mouse variable TNF binding region (25% of 
the protein) and a human Fc fragment (75% of the protein) 
(Elliott et al 1993; Knight et al 1993). The antibody binds 
both the soluble and transmembrane forms of TNF-α with 
high afﬁ  nity and blocks their action (association constant 
1010/M), with a serum half-life of 10 days. It is administered 
intravenously at a dose of 5 or 10 mg/kg (Remicade®). The 
temporal regimens employed in IBD include administration 
on weeks 0, 2, and 6 and then periodically every 8 weeks 
(Rutgeerts et al 2005).
The mechanism of action of inﬂ  iximab is not clearly 
understood. Although initially thought to be mediated via 
neutralization of soluble TNF-α, this is clearly not enough 
because treatment with other anti-TNF-α antibodies and 
soluble TNF-α receptors with similar or even greater 
neutralizing efﬁ  cacy do not exert the same therapeutic effect 
(Remicade®; van Dullemen et al 1995; Hanauer et al 1998). 
Recent investigations suggest that the mechanism of action 
of TNF-α-blocking agents is mediated via apoptosis of TNF-
α-expressing inﬂ  ammatory cells. These studies suggest that 
mucosal T cells of patients with IBD are highly resistant 
to apoptosis (Ina et al 1999; Atreya et al 2000). Resistance 
to apoptosis has been shown in both CD and UC, but the 
mechanism behind this phenomenon seems to differ between 
the two conditions. The intrinsic defect in CD occurs in the 
mitochondrial pathway of apoptosis (imbalance of mitochon-
drial bcl-2/bax), whereas in UC it results from overexpres-
sion of FLICE-inhibitory protein (FLIP) and impairment of 
the caspase-mediated pathway of apoptosis (Peppelenbosch 
and van Deventer 2004). It was shown that inﬂ  iximab can 
induce apoptosis of inﬂ  ammatory cells including T cells and 
monocytes via a caspase-dependent mechanism. This effect 
was independent of Fcγ-R binding or complement activation 
(Tilg et al 2007).
Role of TNF-α in ulcerative colitis
In the intestine, the direct effects of TNF-α on intestinal 
epithelium include disruption of the epithelial barrier, 
induction of apoptosis of epithelial cells, and secretion 
of chemokines from intestinal epithelial cells (Figure 1). 
TNF-α also activates the adaptive immune system of the 
bowel through recruitment and activation of neutrophils 
and macrophages (Guy-Grand et al 1998; Nilsen et al 1998; 
Bischoff et al 1999).
The role of TNF-α in the pathogenesis of IBD has been 
extensively studied and is convincingly established for CD 
(Plevy et al 1997; van Deventer 1997). In UC, the role of 
TNF has been less well characterized (Sands and Kaplan 
2007). There are several examples of a genetic association 
between TNF-α gene polymorphism and susceptibility to 
UC. The frequency of carriers for an increased TNF-α secre-
tion polymorphism (–308A and –238G) was signiﬁ  cantly 
increased in Japanese UC patients compared with healthy 
controls (Wilson et al 1993), while only weak association 
was observed in Chinese UC patients (Cao et al 2006). In 
contrast, in Dutch UC patients, the frequency of the same 
polymorphism site was markedly decreased (Bouma et al 
1996, 1999). A positive transmission disequilibrium of 
another increased TNF-α secretion polymorphism (–857C) 
was shown in a UK UC Caucasian (van Heel et al 2002) 
patient population, while homozygosity for a TNF-α hap-
lotype, (TNF-α, –1031T, –863C, –857C, –380G, –308G, 
–238G) associated with low TNF-α production was shown Biologics: Targets & Therapy 2008:2(3) 382
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to be more prevalent in UC patients with limited compared 
with extensive colitis (Ahmad et al 2003).
Several studies have shown signiﬁ  cant increase in TNF-α 
in colonic mucosa of UC patients (MacDonald et al 1990; 
Murch et al 1993; Breese et al 1994). TNF-α production 
in the colon of UC patients was increased in inﬂ  amed but 
not in noninﬂ  amed areas (van Heel et al 2002). Similarly, 
TNF-α levels in stool samples from patients with active UC 
were signiﬁ  cantly increased compared with healthy controls 
(Braegger et al 1992). Serum levels of TNF-α and TNFR 
were also shown to be signiﬁ  cantly higher in UC patients 
than those of healthy controls and their levels were shown 
to correlate with disease activity (Komatsu et al 2001; Hanai 
et al 2004; Spoettl et al 2007).
In view of the data supporting the importance of TNF-α 
in the pathogenesis of UC and the role inﬂ  iximab plays in 
inducing apoptosis, it was hypothesized that inﬂ  iximab may 
exert a beneﬁ  cial effect in the treatment of moderate to severe 
UC. Initially, anti-TNF-α treatment did not cause disease 
improvement in the experimental colitis Th2 type mouse 
model (oxazolone colitis) (Shen et al 2007). However, this 
model does not reliably mimic human disease. In cotton-top 
tamarins that develop spontaneous UC-like colitis, anti-TNF-α 
treatment markedly improved clinical condition (Watkins et al 
1997). Therefore, studies were conducted to assess its efﬁ  -
cacy in UC in humans. Although several open label studies 
assessed the role of inﬂ  iximab in inducing remission in patients 
with moderate to severe UC (Chey et al 2001; Actis et al 2002; 
Kohn et al 2002; Su et al 2002; Castro Fernandez et al 2003; 
Gornet et al 2003; Armuzzi et al 2004; Bermejo et al 2004; Ljung 
et al 2004; Ochsenkuh et al 2004; Ruiz et al 2004; Kountouras 
et al 2005; Park et al 2005; Iwakura and Ishigame 2006), we 
chose to focus on randomized double-blind placebo-controlled 
studies and on systematic reviews and meta-analysis that 
assessed treatment efﬁ  cacy.
Double blind, placebo-controlled 
studies (see Table 1)
We identiﬁ  ed 5 studies and 2 systematic reviews and meta-
analyses that assessed the efﬁ  cacy of inﬂ  iximab in moder-
ate to severe UC as compared to placebo. These studies 
used different outcome measures to assess their results. 
Figure 1 TNF-α involvement in intestinal inﬂ  ammation. After initial damage to the mucosal barrier, TNF-α is secreted by T lymphocytes, macrophages (Mac), and intestinal 
epithelial cells causing epithelial cell apoptosis, production of cytokines and chemokines, maturation of DCs and activation of tissue metaloproteinases from SC. This in turn 
causes further barrier damage, activation of neutrophils (PMN) and B lymphocytes, up-regulation of adhesion molecules, and further recruitment of inﬂ  ammatory cells.
Abbreviations: IEC, intestinal epithelial cells; DC, dendritic cells; MMP, matrix metalloproteinase; SC, stromal cells.
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Table 1 Double blind, placebo-controlled studies of inﬂ  iximab for UC
Reference Outcome Population Treatment protocol Main result
1 Järnerot et al 2005 Primary: Colectomy or 
death within 90 days after 
infusion. Secondary: clinical 
remission according to the 
Seo index and endoscopic 
remission 1 and 3 months 
after the inﬂ  iximab/placebo 
infusion
45 patients with an 
acute moderate-
severe attack of UC 
that did not respond 
quickly to iv cortico-
steroids
Single infusion of inﬂ  iximab/
placebo in dose of 5 mg/kg
7 (21%) patients in the inﬂ  ix-
imab group and 14 (67%) in the 
placebo group had a colectomy 
(p = 0.017) within 3 months after 
randomization
2 Probert et al 2003 Disease activity 6 weeks 
after the ﬁ  rst infusion using 
the UC scoring system. Two 
end points utilized to deﬁ  ne 
remission: clinical remission 
UC scoring system  2 and 
sigmoidoscopic remission as 
a Baron score of 0
43 patients with UC 
who failed to respond 
to conventional treat-
ment with glucocorti-
coids, and who were 
not in need of urgent 
colectomy
Infusions of inﬂ  iximab 
(5 mg/kg) were given at 
weeks 0 and 2
Six weeks after initiation of treat-
ment, remission rates were 39% 
(9/23) in inﬂ  iximab group vs 30% 
(6/20) in placebo (p = 0.76) and a 
Baron score of 0 (26% (6/23) vs 
30% (6/20)) respectively (p = 0.96)
3 Rutgeerts et al 2005 
(ACT 1)
Clinical response was 
deﬁ  ned as a decrease from 
baseline in the total Mayo 
score of at least 3 points 
with an accompanying 
decrease in the score for 
rectal bleeding of at least 1 
point or an absolute score 
for rectal bleeding of 0 or 
1. Clinical remission was 
deﬁ  ned as a total Mayo 
score of 2 points or lower, 
with no individual score 
exceeding 1 point. Mucosal 
healing was deﬁ  ned as an 
absolute score for endos-
copy of 0 or 1
364 patients with 
moderate-to-severe 
active UC despite 
concurrent treatment 
with corticosteroids 
alone or in combina-
tion with azathio-
prine or 6-MP
Infusion of placebo or inf-
liximab (5 mg or 10 mg/kg) 
at weeks 0, 2, and 6 and 
then every 8 weeks through 
week 46
69% of patients who received 
5 mg of inﬂ  iximab and 61% of 
those who received 10 mg had 
a clinical response at week 8 
compared with 37% of those who 
received placebo (p  0.001 for 
both comparisons with placebo). 
Mucosal healing at weeks 8, 30, and 
54 occurred in signiﬁ  cantly more 
patients in the inﬂ  iximab groups 
than in the placebo groups
4 Rutgeerts et al 2005 
(ACT 2)
Similar to ACT1 364 patients with 
moderate-to-severe 
active ulcerative coli-
tis despite concur-
rent treatment with 
corticosteroids alone 
or in combination 
with azathioprine or 
6-MP and 5-ASA
Infusion of placebo or inf-
liximab (5 mg or 10 mg/kg) 
at weeks 0, 2, and 6 and 
then every 8 weeks through 
week 22
64% and 69% of the patients in 
the 5 and 10 mg inﬂ  iximab groups 
respectively, had a clinical response 
at week 8 compared with 29% 
in the placebo (p  0.001 for 
both comparisons with placebo). 
Mucosal healing at weeks 8 and 
30 occurred in signiﬁ  cantly more 
patients in the inﬂ  iximab groups 
than in the placebo groups
5 Sands et al 2001 The primary endpoint was 
treatment failure deﬁ  ned 
as 1) unachieved clinical 
response as deﬁ  ned by a 
modiﬁ  ed Truelove and Witts 
severity score, 2) increase 
in corticosteroid dosage, 3) 
addition of immunosuppres-
sants, 4) colectomy, or 5) 
death 2 weeks after infusion.
11 patients with 
severe active 
disease for at least 
2 weeks despite of 
at least 5 days of 
corticosteroids
Single infusion of inﬂ  iximab 
at 5, 10, or 20 mg/kg
Four of 8 patients (50%) who 
received inﬂ  iximab were consid-
ered treatment successes at 2 
weeks, compared 0/3 patients who 
received placeboBiologics: Targets & Therapy 2008:2(3) 384
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Additionally, various deﬁ  nitions were used to describe the 
main outcomes. For example, clinical remission has been 
deﬁ  ned as absence of active disease symptoms using True-
love and Witts criteria (the absence of blood and mucus in 
the stool and the absence of diarrhea), or the Lennard-Jones 
criteria (two or less bowel movements a day without other 
signs or symptoms) (Truelove and Witts 1955; Lennard-Jones 
et al 1975; Rutgeerts et al 2005).
It is important to understand that in contrast to CD, in 
which the disease activity index (CDAI) is a well validated 
standardized tool in clinical trials, the outcome measures in UC 
are less well deﬁ  ned. Most trials use a combination of clini-
cal, histological and endoscopic scores to describe remission. 
Others use combined scores which include Physician’s global 
assessment (PGA) scores, ulcerative colitis disease activity 
index (UCDAI), Mayo score, a modified Lennard-Jones 
criteria, Rachmilewitz criteria, or Seo index. The lack of a 
standardized scoring system for UC makes comparison of trial 
results less accurate than comparing results in CD trials and 
makes interpretation of individual trial results prone to bias.
We identiﬁ  ed a systematic review (Gisbert et al 2007), 
search date 2006, and a Cochrane review (Lawson et al 2006), 
search date 2005, that assessed the efﬁ  cacy of inﬂ  iximab in 
inducing remission in moderate to severe UC. Both identiﬁ  ed 
5 randomized, double-blind, placebo-controlled studies; how-
ever, while the systematic review by Gisbert et al reported 
the results in terms of short- and long-term response only, 
the Cochrane review by Lawson et al used a more complex 
approach of reporting on clinical remission and response, 
endoscopic and mucosal responses, and colectomy rates. We 
will describe the studies and the various differences between 
the two meta-analyses.
In the ﬁ  rst double-blind, placebo-controlled trial, Sands 
et al (2001) recruited 11 patients with active severe UC 
as deﬁ  ned by the Truelove and Witts criteria (8 men and 
3 women; age range 20–63). Patients were required to have 
received at least 7 days of corticosteroid treatment and were 
permitted to be treated with immunomodulators excluding 
cyclosporine. Patients were randomly assigned to receive a 
single intravenous infusion of either placebo or inﬂ  iximab 
at 5, 10, or 20 mg/kg. Assessment of outcome was done at 
week 2. The follow-up period was 4 weeks. The study was 
terminated prematurely because of slow enrolment.
Probert et al evaluated 43 patients with moderate UC 
based on ulcerative colitis symptom score (Schroeder et al 
1987) and a sigmoidoscopy score (F/M ratio not given; age 
range 29–50.5) (Probert et al 2003). Patients were required to 
have been treated with corticosteroids for at least 1 week and 
were allowed to have received immunomodulators excluding 
cyclosporine if they were on a stable dose for at least 3 months 
prior to study enrollment. Patients were randomly assigned 
to receive an infusion of 5 mg/kg inﬂ  iximab or placebo at 
week 0 and an identical infusion at week 2. Assessment of 
endpoints was done at week 6, with follow-up for the fol-
lowing 30 days.
Järnerot et al evaluated 45 patients with moderate to 
severe UC according to the Seo index (Seo et al 1992) 
(24 men and 21 women; age range 19–61) (Järnerot et al 
2005). Patients were required to have received at least 
4 days of intravenous corticosteroids. No speciﬁ  c remark 
concerning prior treatment was deﬁ  ned in the inclusion cri-
teria and 8 patients were treated with azathioprine at the time 
of enrollment. Patients were randomized to receive a single 
infusion of 5 mg/kg 4 days after initiation of intravenous 
corticosteroids. Outcome measures were assessed 90 days 
after inﬂ  iximab/placebo infusion.
Rutgeerts et al conducted the two largest studies to date 
that evaluated the efﬁ  cacy of inﬂ  iximab for induction and 
maintenance of remission in UC (Rutgeerts et al 2005). In 
the ACT1 study, 364 patients with moderate to severe colitis 
according to the Mayo Clinic score ( Schroeder et al 1987) 
with active colitis by sigmoidoscopy were recruited (222 
men 142 women; age range 27–55). Patients were required 
to be on concurrent therapy with corticosteroids alone or 
with immunosuppressants. Patients were not required to be 
on concurrent treatment if they had previously not responded 
to these medications. Eligible patients were randomized to 
receive 5 mg/kg, 10 mg/kg of inﬂ  iximab, or placebo in a 
1:1:1 ratio at weeks 0, 2, and 6 and then every 8 weeks for 46 
weeks overall and were followed through week 54. Outcome 
was measured at week 8, 30, and 54.
ACT 2 was similar in design and included 364 patients 
(215 men and 149 women; age range 26–53). Patients 
received 5 mg/kg or 10 mg/kg inﬂ  iximab or placebo in a 1:1:1 
ratio at weeks 0, 2, and 6 and then every 8 weeks through 
week 22 and were followed through week 30.
Interpretation of the results of the studies varied between 
the Cochrane and the systematic review. The systemic review 
by Gisbert et al (2007) evaluated short-term responses of 
inﬂ  iximab vs placebo and found them to be 65% and 33%, 
respectively (95% confidence interval [CI] 61%–69% 
and 27%–38%, respectively). The odds ratio (OR) for the 
response was 3.6 (95% CI 2.67–4.95; p  0.001), the number 
of treatments needed to achieve short-term response was 3 
(95% CI, 3–4) without signiﬁ  cant heterogeneity between the 
studies. Short-term remission was achieved in 33% (95% CI Biologics: Targets & Therapy 2008:2(3) 385
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29%–37%) and 10% (95% CI, 6.4-14%) in the inﬂ  iximab and 
placebo groups, respectively. The OR for the remission was 
4.56 (95% CI 1.98–10.5; p  0.001) with NNT being 4 (95% 
CI 3–6), results being signiﬁ  cantly heterogeneous.
Long-term response was 53% and 24% in the inﬂ  iximab 
and placebo groups (95% CI 49%–58% and 19%–29%), 
respectively. The OR for the rsponse was 3.4 (95% CI 2.52–
4.59; p  0.001) with NNT to achieve long term response 
being 3 (95% CI 3–4) and no signiﬁ  cant heterogeneity. Finally, 
long-term remission was achieved in 33% vs 14% in the inﬂ  ix-
imab and placebo groups (95% CI 29%–37% and 9%–18%), 
respectively. The OR for the remission was 2.72 (95% CI 
1.92–3.38; p  0.001) without signiﬁ  cant heterogeneity and 
NNT to achieve long-term remission being 5 (95% CI 4–7).
The Cochrane review (Lawson et al 2006) adopted a 
slightly different approach, describing the results in terms 
of reaching pre-deﬁ  ned end points.
Clinical remission
This endpoint was described in only 4 trials. The authors 
combined the ACT1 and ACT2 trials for the purpose of meta-
analysis and reported the other two studies separately because 
of different outcome measures. Inﬂ  iximab was effective for 
the induction of clinical remission at 8 weeks (relative risk 
[RR] 3.22, 95% CI 2.18–4.16, NNT = 5). There was no sig-
niﬁ  cant difference in the results for the subgroup analysis of 
5 mg/kg and 10 mg/kg of inﬂ  iximab. The two small studies 
that reported this outcome showed a trend favoring inﬂ  iximab 
but failed to reach statistical signiﬁ  cance (Probert et al 2003; 
Järnerot et al 2005).
Endoscopic remission/mucosal healing
This outcome was also described in 4 studies. The two 
smaller studies did not reach statistical signiﬁ  cance. The two 
larger studies were grouped for meta-analysis. Inﬂ  iximab 
was effective in inducing endoscopic remission and mucosal 
healing at 8 weeks (RR 1.88, 95% CI 1.54–2.28, NNT = 4) 
without heterogeneity.
Clinical response
This endpoint was assessed in the ACT trials. inﬂ  iximab 
effectively induced a clinical response (RR 1.99, 95% CI 1.65–
2.41, NNT = 4) and there was moderate heterogeneity.
Treatment success
This outcome was assessed in only one small trial (Sands 
et al 2001). There was no statistical signiﬁ  cance between 
inﬂ  iximab and placebo.
Colectomy
This outcome was only described in one study (Järnerot et al 
2005). There was a signiﬁ  cant reduction in rates of colectomy 
with inﬂ  iximab (RR, 95% CI 0.22–0.78).
Quality of life
This outcome measure was assessed in one study (Probert et al 
2003). Using a standard questionnaire (IBDQ), the authors did 
not ﬁ  nd a statistically signiﬁ  cant difference between inﬂ  ix-
imab and placebo in improving the quality of life.
Safety
Adverse events related to inﬂ  iximab were generally mild 
and did not differ between the treatment and placebo groups. 
Patients in the inﬂ  iximab groups developed headache, upper 
respiratory tract infection, pruritus, nephrolithiasis, and 
catheter insertion complication. Recently, concerns regarding 
the issue of severe infections including tuberculosis and the 
development of lymphoma after inﬂ  iximab treatment were 
raised. In the ACT1 and ACT2 studies, one patient treated 
with inﬂ  iximab in each trial developed serious infections, 
one a case of tuberculosis, and the other fatal histoplasmosis. 
Patients in the inﬂ  iximab groups were more likely to develop 
auto-antibodies than patients in the placebo groups.
Discussion and summary
IBD is a chronic disease with a relapsing and remitting course. 
Its pathogenesis involves a dysregulated immune response 
to luminal antigens in patients with a genetic susceptibility. 
IBD comprises of two distinct clinical entities, UC and CD. 
Despite immunologic differences between them, TNF-α, a 
pro-inﬂ  ammatory cytokine, is hypothesized to play a key 
role in regulating the pathogenesis of both diseases. Therapy 
directed at blocking TNF-α action was shown to result in 
clinical improvement in patients with moderate to severe CD. 
In UC the role of TNF-α is less well established; however, 
there is mounting evidence that TNF-α gene polymorphisms 
are associated with disease extent and severity. Also, TNF-α 
levels were shown to be elevated in colonic tissue, feces, 
and serum of patients with UC and to correlate with disease 
severity. Initial studies evaluating the efﬁ  cacy of anti-TNF-α 
treatment in moderate to severe UC showed relative success in 
inducing remission and in achieving clinical response. Most 
of these early studies were small and uncontrolled. Since 
then, 5 randomized placebo-controlled studies enrolling 827 
patients assessed the efﬁ  cacy of inﬂ  iximab treatment in UC. 
The studies were heterogeneous. Three were small (less then 
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The studies utilized different outcome measures, making 
the results hard to compare. Two of the small studies did 
not show clinical beneﬁ  t of inﬂ  iximab (Probert et al 2003; 
Sands et al 2001), raising the possibility of a type II error. 
The other three studies all showed clinical beneﬁ  t to inﬂ  ix-
imab (Järnerot et al 2005; Rutgeerts et al 2005); however, 
they did not assess the same endpoints. The smaller study 
by Järnerot et al (2005) showed a reduction in the rates of 
colectomy but did not look at remission. The study was small 
(45 patients) and the follow-up short (13 weeks). The two 
larger studies by Rutgeerts et al (2005) showed beneﬁ  t in 
induction of remission, clinical response, discontinuing of 
corticosteroids, and mucosal healing in the groups treated 
with inﬂ  iximab, but did not assess rates of colectomy. 
Based on the three studies and the two systematic reviews, 
inﬂ  iximab is effective in inducing remission and improving 
clinical response in patients with moderate to severe UC. 
One study showed reduced rates of colectomy and two small 
studies did not ﬁ  nd any beneﬁ  t from inﬂ  iximab treatment. 
The proportion of patients who reported adverse events 
were similar between the treatment and placebo groups. 
Most adverse events were mild. In the ACT1 and ACT2 
studies, there was a slight increase in the number of serious 
infections, neurological complications, and lupus-like reac-
tions in the inﬂ  iximab groups with one fatal disseminated 
histoplasmosis.
Until recently, the only available medical treatment for 
patients with moderate to severe UC that failed conven-
tional treatment was cyclosporine. Although inﬂ  iximab is 
sometimes considered an alternative to cyclosporine, we 
believe that no competition should actually exist between 
the two drugs: inﬂ  iximab has a slower mode of action and is 
used to beneﬁ  t moderate to severe UC in ambulatory patients. 
Cyclosporine continues to be the only effective alternative 
to emergency colectomy in patients hospitalized for severe 
fulminant disease. The role of combined cyclosporine and 
inﬂ  iximab has not been assessed and would increase the risk 
of profound immunosuppression. There are already reports 
of an increase in peri-operative infections in UC patients 
undergoing colectomy after treatment with both inﬂ  iximab 
and cyclosporine.
The data reviewed here emphasizes the importance of 
establishing a uniform scoring system to UC similar to the 
one used in CD. Such a scoring system will enable appropri-
ate comparison of clinical outcomes and assist in conduct-
ing adequate drug trials in UC. Special attention should be 
given to elucidating the mechanism of action of inﬂ  iximab. 
Understanding the role of TNF-α and other mediators in the 
pathogenesis of UC will enhance our ability to design new 
drugs that will target key chemokines and cytokines regula-
tors of the intestinal inﬂ  ammatory process. Although the trials 
provide an answer to the question concerning the place of 
inﬂ  iximab in the treatment of moderate to severe UC, several 
clinical questions remain unanswered. What is the role of 
inﬂ  iximab in inducing remission in mild to moderate UC? 
What is the role of inﬂ  iximab in maintenance of remission? 
Can inﬂ  iximab be used for the treatment of extra-intestinal 
manifestations of UC? Is there a role for inﬂ  iximab in the 
treatment of pouchitis? These questions will have to await 
the results of future well designed, double-blind, placebo-
controlled trials.
Abbreviations
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